/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
We are a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. Our product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that we are developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comor…
$28.02
+$0.04 (+0.14%)
EOD Sep 18, 2026
Negative free cash flow of -$142M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$350M
▲ +13.0% YoY
Op. Margin
—
ROIC
-48.57%
▲ +38.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$139M
▲ +14.4% YoY
Op. Cash Flow (TTM)
-$139M
▲ +14.4% YoY
Net Debt
-$138M
Net Cash Position
Cash & Equiv.
$138M
Continue Research
SourceComputed from the 10-Q filed 11 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 12 Aug 2026. How this is calculated.
Price from market data, last close as of 18 Sept 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.